Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

627 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of gefitinib on warfarin antithrombotic activity.
Arai S, Mitsufuji H, Nishii Y, Onoda S, Ryuge S, Wada M, Katono K, Iwasaki M, Takakura A, Otani S, Yamamoto M, Yanaihara T, Yokoba M, Kubota M, Katagiri M, Fukui T, Kobayashi H, Yanase N, Hataishi R, Masuda N. Arai S, et al. Among authors: katagiri m. Int J Clin Oncol. 2009 Aug;14(4):332-6. doi: 10.1007/s10147-008-0871-2. Epub 2009 Aug 25. Int J Clin Oncol. 2009. PMID: 19705244
Drug interaction between gefitinib and warfarin.
Onoda S, Mitsufuji H, Yanase N, Ryuge S, Kato E, Wada M, Ishii K, Hagiri S, Yamamoto M, Yokoba M, Yanaihara T, Kuboto M, Takada N, Katagiri M, Abe T, Tanaka N, Kobayashi H, Masuda N. Onoda S, et al. Among authors: katagiri m. Jpn J Clin Oncol. 2005 Aug;35(8):478-82. doi: 10.1093/jjco/hyi122. Epub 2005 Jul 8. Jpn J Clin Oncol. 2005. PMID: 16006576
Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer.
Igawa S, Ryuge S, Fukui T, Otani S, Kimura Y, Katono K, Takakura A, Kubota M, Mitsufuji H, Katagiri M, Yanase N, Masuda N. Igawa S, et al. Among authors: katagiri m. Int J Clin Oncol. 2010 Oct;15(5):447-52. doi: 10.1007/s10147-010-0085-2. Epub 2010 May 13. Int J Clin Oncol. 2010. PMID: 20464623
Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
Otani S, Hamada A, Sasaki J, Wada M, Yamamoto M, Ryuge S, Takakura A, Fukui T, Yokoba M, Mitsufuji H, Toyooka I, Maki S, Kimura M, Hayashi N, Ishihara M, Kasajima M, Hiyoshi Y, Katono K, Asakuma M, Igawa S, Kubota M, Katagiri M, Saito H, Masuda N. Otani S, et al. Among authors: katagiri m. Am J Clin Oncol. 2015 Aug;38(4):405-10. doi: 10.1097/COC.0b013e3182a2d98d. Am J Clin Oncol. 2015. PMID: 26214085 Clinical Trial.
Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Nishinarita N, Igawa S, Kasajima M, Kusuhara S, Harada S, Okuma Y, Sugita K, Ozawa T, Fukui T, Mitsufuji H, Yokoba M, Katagiri M, Kubota M, Sasaki J, Naoki K. Nishinarita N, et al. Among authors: katagiri m. Oncology. 2018;95(2):109-115. doi: 10.1159/000488594. Epub 2018 Apr 26. Oncology. 2018. PMID: 29698957
Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer.
Yanaihara T, Yokoba M, Onoda S, Yamamoto M, Ryuge S, Hagiri S, Katagiri M, Wada M, Mitsufuji H, Kubota M, Arai S, Kobayashi H, Yanase N, Abe T, Masuda N. Yanaihara T, et al. Among authors: katagiri m. Cancer Chemother Pharmacol. 2007 Mar;59(4):419-27. doi: 10.1007/s00280-006-0279-5. Epub 2006 Jul 11. Cancer Chemother Pharmacol. 2007. PMID: 16832665 Clinical Trial.
627 results